| |
2nd Annual New England Protein
Science Forum
New Techniques in Protein Sciences - developments in protein science for biopharma and drug discovery
Bentley College, Waltham
Friday, November 7, 2008
Agenda
|
8:00 am |
|
Check-in and light breakfast |
9:00—9:10 |
|
Introduction
Rajiv Chopra, NESBA |
|
|
Session I—Overcoming Challenges in Protein Expression & Purification
(Session chair: Ian Hunt) |
9:10—9:45 |
|
Overcoming the challenges in supplying proteins for drug discovery;
tricks and lessons learned in producing difficult to express proteins
Xin Huang, Amgen, Cambridge, MA
|
9:45—10:20 |
|
E.coli and Baculovirus generated proteins for structure based drug
design
James M. Groarke, Protein Structure Group, Novartis Institute for Biomedical
Research, Cambridge, MA
|
10:20—10:55 |
|
PER.C6® a Human Cell Line Expression
platform
Blanca Lain, PERCIVIA, LLC, Cambridge, MA
|
10:55—11:10 |
|
Coffee Break and Posters Session |
|
|
Session II—Advances in protein analytics & expression technologies
(Session chair: Ted Fox) |
11:10—11:45 |
|
Proteomics—Discovery and Translation of Biomarkers for Early
Clinical Development
Cloud Paweletz, Molecular Profiling Proteomics, Merck Research Laboratories,
Boston, MA
|
11:45—12:20 |
|
Analytical Untracentrifugation Applied to Drug Discovery and
Development
John Doran, Vertex, Cambridge, MA
|
12:20—1:00 |
|
Lunch |
|
|
Session IIIA—Biologics & Vaccines: Current trends and developments
(Session chair: Simon Low) |
1:00—2:00 |
|
Keynote Speaker:
Stapled Peptides: A New Therapeutic Modality
Tomi Sawyer, Aileron Therapeutics, Cambridge, MA
|
2:00—2:35 |
|
Adnectins: Novel Targeted Biologics
Jochem Gokemeijer, Adnexus, Waltham, MA
|
2:35—2:50 |
|
Break and Posters Session |
|
|
Session IIIB—Biologics & Vaccines: Current trends and developments
(Session chair: Stephen Chambers) |
2:50—3:25 |
|
From Gene to a Marketed Biologic: An Overview of the Process and
Points to Consider
Darren Baker, Biogen Idec, Cambridge, MA
|
3:25—4:00 |
|
Production, Biochemical, Biophysical, and Immunological
Characterization of Vaccines
Indresh Srivastava, Novartis Vaccines, Cambridge, MA
|
4:00—4:35 |
|
Biological Therapeutics by Design Using Engineered Heterodimeric Fc
Domains
Jonathan Davis, Adnexus, Waltham, MA
|
4:35 onwards
|
|
Mixer and Posters Session |
Register now!
| Meeting sponsors
|
